

750 **Supplementary Data**

751

Study	Study design	Number of participants	Mean age	Sex	Mean disease duration in years
Elias et. al, 2013 ⁵	Prospective	15	66.6±8	67% male	32±21.3 years
Elias et. al, 2016 ⁴	Randomized trial	Treatment arm: 56 Sham/crossover arm: 20	Treatment arm: 70.8±8.7 Sham/crossover arm: 71.4 ± 7.3	Treatment arm: 66% male Sham/crossover arm: 75% male	Treatment arm: 28.3±16.4 years Sham/crossover arm: 27.9±14.9
Chang et. al, 2017 ⁶	Prospective	76	71.0 ± 8.3	68% male	16.8 ± 12.3 years
Halpern et. al, 2019 ⁷	Prospective	75	71.0 ± 8.3		16.8 ± 12.3
Park et. al, 2019 ⁸	Prospective	12	61.7 ± 8.1	83% male	17.8 ± 13.03 years
Zur et. al, 2020 ⁹	Prospective	Initial arm: 22 Replication arm: 17	Initial arm: 72 years ± 6 Replication arm: 73±6	Initial arm: 63% male Replication arm: 59% male	Initial arm: 13± 8 Replication arm: 12±9
Wu et. al, 2021 ¹⁰	Prospective	48	59.14 ± 13.5 y	65% male	19.2 ± 13.6
Fukutome et. al, 2021 ¹¹	Prospective	15	62.9 ± 11.3 years	73% male	21.5 ± 14.0
Purrer et. al, 2022 ¹²	Prospective	37	69.4 ± 12.2	68% male	29.8 ± 16.4
Cosgrove et. al, 2023 ¹³	Prospective	76	At 5 year follow up, mean age of 75 ± 8.4	75% male	

752 Table 1: Demographic details for patients included in Figure 3.

753

Study	Number of participants	Baseline CRST(Clinical Rating Score for Tremor) hand score	Score at 6 months	Score at 12 months	Score at 60 months
Elias et. al, 2013 ⁵	15	20.4±5.2		5.2±4.8	
Elias et. al, 2016 ⁴	Treatment arm: 56 patients Crossover patients: 21 Sham: 11	Treatment arm: 18.1±4.8 Crossover arm: 16.5±4.2 Sham arm: 16±4.4	Treatment arm: 10.1±5.3 Crossover arm: 8±3.9	Treatment arm: 10.9±4.5 Crossover arm: 6.71±4.7	
Chang et. al, 2017 ⁶	76	19.8 ± 4.9	8.6 ± 4.5	8.9 ± 4.8	
Halpern et. al, 2019 ⁷	75	20.1 ± 4.7	8.6 ± 4.5	8.9 ± 4.8	
Park et. al, 2019 ⁸	12	17.4 ± 3.8	5 ± 3.3	5.3 ± 3.4	
Zur et. al, 2020 ⁹	Initial arm: 22 Replication arm***: 17	Initial arm: 19.2±6.9 Replication arm: 18.2±4.3	Initial arm: 4±4		
Wu et. al, 2021 ¹⁰	48	14.7 ± 4.9	6.6 ± 5.3	7.0 ± 5.5	
Fukutome et. al, 2021 ¹¹	15	18.5 ± 5.8		4.6 ± 5.7	
Purrer et. al, 2022 ¹²	37	19.2 ± 4.2	5.6 ± 4.4	6.2 ± 5.0	
Cosgrove et. al, 2023 ¹³	40 patients at 5 year follow up	20 ± 4.7		8.9 ± 4.8	9.5 ± 5.4

754 Table 2: Change in CRST (Clinical Rating Score for Tremor) hand scores post-HiFU.

Study	Study design	Number of participants	Number of participants	Mean age	Sex	Mean disease duration in years
Bond et. al, 2017 ²⁰	Randomized trial	Treatment arm: 20 Sham arm: 7	Treatment arm: 20 Sham arm: 7	Treatment arm: 68.1 Sham arm: 62.4	Treatment arm: 95% male Sham arm: 100% male	Treatment arm: 5.9 (median) Sham arm: 6.7 (median)
Yamamoto et. al, 2021 ²¹	Prospective	11	11	71.6 ± 6.8	46% male	6.0
Jung et. al, 2019 ²²	Prospective	10 patients total*	10	59.8	40% male	10.1
Ito et. al, 2020 ²³	Prospective	3	10	67.1±17.5	80% male	
Eisenberg et. al, 2021 ²⁴	Prospective	20	20	56.4±11.3	65% male	9.9±6.4
Martinez-Fernandez et. al, 2018 ²⁵	Prospective	10 patients	10	59.5	60% male	6.3
Martinez-Fernandez et. al, 2020 ²⁶	Randomized trial	Treatment arm: 27 Sham arm: 13	Treatment arm: 27 Sham arm: 13	57.1±9.1	65%	6.2±3.0 years

756

757 Table 3: Demographic Data for Patients included in Figures 6, 7 and 8.